Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al

Philipp Harter; Alexander Reuss; Jalid Sehouli; Luis Chiva; Andreas du Bois

doi:10.1097/IGC.0000000000000864

Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al

Int J Gynecol Cancer. 2017 Feb;27(2):246-247. doi: 10.1097/IGC.0000000000000864.

Authors

Philipp Harter¹, Alexander Reuss, Jalid Sehouli, Luis Chiva, Andreas du Bois

Affiliation

¹ *Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen; †Coordinating Center for Clinical Trials, Philipps-University Marburg, Marburg; ‡Department of Gynecology, Charité, Berlin, Germany; and §Department of Gynecology Oncology, MD Anderson Cancer Center, Madrid, Spain.

PMID: 28114231
DOI: 10.1097/IGC.0000000000000864

Abstract

A published so-called phase 3 study regarding HIPEC in ovarian cancer raised multiple questions. This commentary focusses on the weakness of the publication and discusses this in detail.

Publication types

Comment

MeSH terms

Carcinoma, Ovarian Epithelial*
Combined Modality Therapy
Cytoreduction Surgical Procedures
Female
Humans
Hyperthermia, Induced*
Neoplasm Recurrence, Local
Ovarian Neoplasms*
Prospective Studies